Evidence map›Paper›PMID 25970334›Full record

ArticlePloS one2015

Effects of valproic acid and dexamethasone administration on early bio-markers and gene expression profile in acute kidney ischemia-reperfusion injury in the rat.

Ryan W Speir, Jonathan D Stallings, Jared M Andrews, Mary S Gelnett, Timothy C Brand, Shashikumar K Salgar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. The analysis of a time-course transcriptome profile by systems biology approaches reveals key molecular processes in acute kidney injury.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Late intervention with the small molecule BB3 mitigates postischemic kidney injury.American journal of physiology. Renal physiology · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ryan W SpeirDepartment of Surgery, Madigan Army Medical Center, Tacoma, Fort Lewis, Washington, United States of America.
Jonathan D StallingsEnvironmental Health Program, US Army Center for Environmental Health Research, Fort Detrick, Maryland, United States of America.
Jared M AndrewsDepartment of Pathology, Madigan Army Medical Center, Tacoma, Fort Lewis, Washington, United States of America.
Mary S GelnettDepartment of Pathology, Madigan Army Medical Center, Tacoma, Fort Lewis, Washington, United States of America.
Timothy C BrandDepartment of Surgery, Madigan Army Medical Center, Tacoma, Fort Lewis, Washington, United States of America.
Shashikumar K SalgarDepartment of Clinical Investigation, Madigan Army Medical Center, Tacoma, Fort Lewis, Washington, United States of America.
Madigan Army Medical Center · USCenter for Environmental Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal ischemia-reperfusion (IR) causes acute kidney injury (AKI) with high mortality and morbidity. The objective of this investigation was to ameliorate kidney IR injury and identify novel biomarkers for kidney injury and repair. Under general anesthesia, left renal ischemia was induced in Wister rats by occluding renal artery for 45 minutes, followed by reperfusion and right nephrectomy. Thirty minutes prior to ischemia, rats (n = 8/group) received Valproic Acid (150 mg/kg; VPA), Dexamethasone (3 mg/kg; Dex) or Vehicle (saline) intraperitoneally. Animals were sacrificed at 3, 24 or 120 h post-IR. Plasma creatinine (mg/dL) at 24 h was reduced (P<0.05) in VPA (2.7±1.8) and Dex (2.3±1.2) compared to Vehicle (3.8±0.5) group. At 3 h, urine albumin (mg/mL) was higher in Vehicle (1.47±0.10), VPA (0.84±0.62) and Dex (1.04±0.73) compared to naïve (uninjured/untreated control) (0.14±0.26) group. At 24 h post-IR urine lipocalin-2 (μg/mL) was higher (P<0.05) in VPA, Dex and Vehicle groups (9.61-11.36) compared to naïve group (0.67±0.29); also, kidney injury molecule-1 (KIM-1; ng/mL) was higher (P<0.05) in VPA, Dex and Vehicle groups (13.7-18.7) compared to naïve group (1.7±1.9). Histopathology demonstrated reduced (P<0.05) ischemic injury in the renal cortex in VPA (Grade 1.6±1.5) compared to Vehicle (Grade 2.9±1.1). Inflammatory cytokines IL1β and IL6 were downregulated and anti-apoptotic molecule BCL2 was upregulated in VPA group. Furthermore, kidney DNA microarray demonstrated reduced injury, stress, and apoptosis related gene expression in the VPA administered rats. VPA appears to ameliorate kidney IR injury via reduced inflammatory cytokine, apoptosis/stress related gene expression, and improved regeneration. KIM-1, lipocalin-2 and albumin appear to be promising early urine biomarkers for the diagnosis of AKI.

Indexed as

TranscriptomeAnimalsAnti-Inflammatory AgentsApoptosisBiomarkersCell Adhesion MoleculesDexamethasoneDrug Evaluation, PreclinicalInjections, IntraperitonealKidneyLipocalin-2LipocalinsMaleProto-Oncogene Proteins c-bcl-2Rats, WistarReperfusion InjuryAnti-Inflammatory AgentsBiomarkersCell Adhesion MoleculesDexamethasoneHavcr1 protein, ratLcn2 protein, ratLipocalin-2LipocalinsProto-Oncogene Proteins c-bcl-2Valproic Acid

Identifiers

PMID25970334
PMCPMC4430309
OpenAlexW285339583

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.